Drug Approval | July 24, 2025
Lupin receives USFDA approvals for Liraglutide and Glucagon injectable products
Both these products will be manufactured at Lupin’s Injectable facility at Nagpur, India
Both these products will be manufactured at Lupin’s Injectable facility at Nagpur, India
3SBio will receive a payment of $1.25 billion. Pfizer will also make a $100 million equity investment in 3SBio
Upgrades 2025 full-year CDMO sales and margin outlook
Combined strength of two brands across 11 states to elevate patient care delivery and access to doctors
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
Reblozyl is a standard of care for the first-line treatment of anemia without previous erythropoiesis stimulating agent use
Aims to support healthcare practitioners with evidence-based cough categorization tools that enable choosing the right molecules for effective & targeted relief from cough
Plant-based chemistries have an outsized role to play for the HPC sector by meeting demand for good, gentle, and green products
This marks the fourth acquisition by Corona Remedies from multinational corporations
Enables additional US manufacturing capacity to serve increased demand for pharma/biotech customers
Subscribe To Our Newsletter & Stay Updated
